

Contents

List of Contributors
Preface

xix
xxiii

Section I Introduction

1. Digestive System and Autoimmunity

H. Mix, M.P. Manns

1. The Digestive System and Gut-Associated Immunity	3
2. Self-Tolerance and Autoimmunity	7
3. Tolerance Mechanisms for Autoreactive B Cells in the Bone Marrow	8
4. Tolerance Mechanisms for Autoreactive T Cells in the Thymus	8
5. Clonal Anergy and Tuning	9
6. Extrinsic Controls of Self-Reactive Lymphocytes	10
7. Limitation of Costimuli	10
8. Regulation of Self-Reactive Lymphocytes in Follicles	11
9. Tolerance at the Effector Phase	12
10. Conclusions	12
References	12

2. Immunopathogenesis of Autoimmune Liver Damage

A.J. Czaja

1. Introduction	19
2. Antigens and Antigen Responses	20
2.1 Target Antigen(s)	20
2.2 Molecular Mimicry	22
2.3 Promiscuous Lymphocyte Targeting	23
3. Molecular Mechanisms of Liver Cell Injury	25
3.1 Chemokines and Cell Trafficking	25
3.2 Pro- and Antiinflammatory Cytokines	25
3.3 Apoptotic Activity	27
3.4 Hepatocyte Necrosis	29
3.5 Oxidative Stress	29
3.6 Nitrosative Stress	30

4.	Cellular Mediators of Liver Cell Injury	31
4.1	Innate and Adaptive Immune Responses	31
4.2	Natural Killer T Cells	32
4.3	Gamma Delta Lymphocytes	32
4.4	Regulatory T Cells	35
5.	Genetic Predispositions	36
5.1	Associations Within the Major Histocompatibility Complex	36
5.2	Associations Outside the Major Histocompatibility Complex	38
	References	39
3.	Autoantibodies in Gastrointestinal Autoimmune Diseases	
	<i>D. Ben-Ami Shor, N.P. Papageorgiou, Y. Shoenfeld</i>	
1.	Antibodies in Inflammatory Bowel Diseases	49
1.1	The Antibodies	49
1.2	Genetics	50
1.3	Pathogenic Role	51
1.4	Sensitivity and Specificity of Anti- <i>Saccharomyces cerevisiae</i> Antibodies	51
1.5	Clinical Practice	52
2.	Antibodies in Celiac Disease	52
2.1	The Antibodies	53
2.2	Pathogenic Role	54
2.3	Genetics	54
2.4	Sensitivity and Specificity	54
2.5	Clinical Practice	56
3.	Antibodies in Autoimmune Liver Diseases	56
3.1	The Antibodies	57
3.2	Genetics	61
3.3	Pathogenic Role	61
4.	Clinical Practice	62
	References	62
4.	Imaging Techniques in Digestive Diseases	
	<i>C. Ayuso, M. Pagés, L. Donoso</i>	
1.	Introduction	67
2.	Imaging Modalities	67
2.1	Plain Abdominal Film and Barium Studies	67
2.2	Ultrasound or Ultrasonography	68
2.3	Computed Tomography	69
2.4	Magnetic Resonance	74
2.5	Positron Emission Tomography	78
3.	Future Prospects	79
	References	79

Section II

Autoimmune Liver Diseases

5. Primary Biliary Cholangitis

R. Abdalian, J. Heathcote, M. Ramos-Casals

1. Introduction	83
2. Epidemiological Highlights	84
3. Pathophysiological Insights	85
4. Clinical Presentations	88
5. Natural History and Prognostic Considerations	90
6. Treatment Considerations	91
7. Conclusion	92
8. Five-Year Update	93
8.1 Changing Nomenclature	93
8.2 Autoantibodies	93
8.3 Bile Acid–Based New Therapies	94
8.4 Biological Therapies	95
8.5 Antifibrotic Agents	96
8.6 Targeting Multiple Etiopathogenic Pathways	96
References	96

6. Autoimmune Hepatitis

D. Vergani, G. Mieli-Vergani

1. Introduction	103
2. History and Epidemiology	104
3. Clinical Features	104
4. Diagnosis and Laboratory Findings	105
5. Pathophysiology	107
5.1 Genetics	107
5.2 Immune Mechanisms	108
6. Management and Prognosis	111
7. Autoimmune Hepatitis and Liver Transplant	113
7.1 Recurrence of Autoimmune Hepatitis After Transplant	113
7.2 De Novo Autoimmune Hepatitis After Transplant	114
8. Conclusion	115
References	115

7. Primary Sclerosing Cholangitis

R.W. Chapman, K.D. Williamson

1. Introduction	120
2. Epidemiology	120
3. Etiopathogenesis	121
3.1 Genetic Factors	121
3.2 Other Proposed Mechanisms	122

4. Clinical Features	123
4.1 Symptoms and Signs	123
4.2 Serology	123
5. Diagnosis	124
5.1 Laboratory Investigations	124
5.2 Radiological Features	124
5.3 Liver Histology	125
6. Special Patient Populations	126
6.1 Secondary Sclerosing Cholangitis	126
6.2 Small Duct Primary Sclerosing Cholangitis	126
6.3 Autoimmune Hepatitis Overlap	127
6.4 IgG4-Related Sclerosing Cholangitis	127
6.5 High Serum IgG4 Levels in Primary Sclerosing Cholangitis	128
7. Inflammatory Bowel Disease in Primary Sclerosing Cholangitis	128
8. Primary Sclerosing Cholangitis and Malignancy	129
8.1 Colorectal Cancer	129
8.2 Cholangiocarcinoma	129
8.3 Gallbladder, Pancreatic Cancer, and Hepatoma	131
9. Nonmalignant Complications	131
9.1 Dominant Strictures	131
9.2 Metabolic Bone Disease	132
10. Natural History of Disease	132
10.1 Prognosis	132
10.2 Prognostic Models	132
11. Treatment	133
11.1 Treatment of Complications	133
11.2 Specific Medical Treatment	133
11.3 Liver Transplantation	134
12. Conclusion	134
References	135

Section III

Autoimmune Manifestations of Viral Hepatitis

8. Systemic and Autoimmune Manifestations of Hepatitis B Virus Infection

C. Pagnoux, L. Guillevin

1. Introduction	143
2. Hepatitis B Virus Infection	144
2.1 Main Viral Characteristics	144
2.2 Hepatitis B Virus Infection and Diagnosis	144
3. Extrahepatic Manifestations of Hepatitis B Virus Infection	146
3.1 Prodromal Preicteric Syndrome	146
3.2 Hepatitis B Virus--Associated Vasculitis	147

3.3	Hepatitis B Virus—Related Glomerulonephritis	155
3.4	Gianotti—Crosti Syndrome	156
3.5	Porphyria Cutanea Tarda	157
3.6	Diabetes Mellitus	158
3.7	Metabolic Syndrome	159
3.8	Thyroid Manifestations	160
3.9	Autoimmune Manifestations	160
3.10	Miscellaneous	161
	Key Points	163
	References	164

9. Extrahepatic Manifestations in Patients With Chronic Hepatitis C Virus Infection

P. Brito-Zerón, S. Retamozo, X. Forns, J.-M. Sanchez-Tapias, J.R. Teixidor, M. Ramos-Casals

1.	Introduction	173
2.	Autoantibodies and Hepatitis C Virus	174
3.	Organ-Specific Autoimmune Diseases and Hepatitis C Virus	175
3.1	Thyroiditis	175
3.2	Diabetes Mellitus and Steatosis	175
4.	Systemic Autoimmune Diseases and Hepatitis C Virus	176
4.1	Sjögren Syndrome	176
4.2	Rheumatoid Arthritis	179
4.3	Systemic Lupus Erythematosus	180
4.4	Antiphospholipid Syndrome	182
4.5	Cryoglobulinemic Vasculitis	182
4.6	Sarcoidosis	184
4.7	Noncryoglobulinemic Systemic Vasculitis	188
4.8	Inflammatory Myopathies	189
4.9	Other Systemic Autoimmune Diseases	189
5.	Hematological Diseases and Hepatitis C Virus	190
5.1	Autoimmune Cytopenias	190
5.2	Lymphoproliferative Diseases	191
	References	194

10. New Antivirals for Extrahepatic Manifestations of Hepatitis C Virus: The Model of Mixed Cryoglobulinemia Vasculitis

P. Cacoub, A.C. Desbois, M. Vauthier, C. Commarmond, F. Domont, L. Savy, D. Saadoun

1.	Introduction	203
2.	Treatment of Hepatitis C Virus—Mixed Cryoglobulinemia Vasculitis	204
2.1	Antiviral Agents	205

2.2 Other Nonvirological Treatments	207
2.3 Therapeutic Guidelines	208
References	209

Section IV

Gastrointestinal Involvement of Systemic Diseases

11. Systemic Lupus Erythematosus

M. Vilardell-Tarrés, A. Selva-O'Callaghan, J. Ordi-Ros

1. Introduction	215
2. Overview of Gastrointestinal Manifestations in Systemic Lupus Erythematosus	215
3. Oral Cavity, Esophagus, and Gastrointestinal Abnormalities	217
4. Main Identifiable Lupus-Related Gastrointestinal Syndromes	219
4.1 Lupus Mesenteric Vasculitis	219
4.2 Intestinal Pseudoobstruction	220
4.3 Protein-Losing Enteropathy	222
5. Lupus-Associated Pancreatitis	223
6. Other Systemic Lupus Erythematosus-Related Gastrointestinal Problems	223
References	224

12. Digestive Involvement in the Antiphospholipid Syndrome

I. Rodríguez-Pintó, G. Espinosa, R. Cervera

1. Introduction	227
2. Gastrointestinal Involvement	228
2.1 Ischemic Gastrointestinal Involvement	228
2.2 Inflammatory Bowel Disease and Antiphospholipid Syndrome	231
3. Hepatic Involvement	231
3.1 Vascular Liver Disease	231
3.2 Autoimmune Liver Disease	233
3.3 Liver Cirrhosis	235
3.4 Liver Transplant	236
4. Splenic Involvement	236
4.1 Splenic Ischemic Disease	236
4.2 Autosplenectomy or Functional Asplenia	236
5. Pancreatic Involvement	237
References	237

13. Gastrointestinal Involvement in Systemic Sclerosis

A.B. Shreiner, D. Khanna

1. Introduction	243
2. Pathogenesis of Gastrointestinal Tract Dysmotility	243

3. Esophagus	244
3.1 Esophageal Dysmotility	244
3.2 Gastroesophageal Reflux Disease	245
3.3 Barrett Esophagus	249
4. Stomach	249
4.1 Gastroparesis	249
4.2 Gastric Antral Vascular Ectasia	250
5. Small Intestine	251
5.1 Intestinal Pseudoobstruction	251
5.2 Small Intestinal Bacterial Overgrowth	252
5.3 Pneumatosis Cystoides Intestinalis	253
5.4 Malnutrition	253
6. Colon and Anorectal Disorders	254
6.1 Colon Involvement	254
6.2 Anorectal Dysfunction	254
7. Patient-Reported Outcome Measures	255
8. Conclusion	256
References	256

14. Gastrointestinal Involvement in Inflammatory Myositis

*M. Pérez-de-Lis Novo, R. Pérez-Álvarez, L. Pallarés-Ferreres,
J.J. Fernández-Martín, M.-J. Soto Cárdenas, A. Selva-O'Callaghan*

1. Introduction	263
2. Dysphagia	263
3. Gastric Involvement	264
4. Gastrointestinal Vasculitis and Inflammation	264
5. Pneumatosis Cystoides Intestinalis	265
6. Overlap With Inflammatory Bowel Disease	266
7. Overlap With Coeliac Disease	266
8. Association With Chronic Viral Infections	266
9. Diagnosis and Differential Diagnosis	267
10. Therapeutic Management	267
References	268

15. Digestive Involvement in Primary Sjögren's Syndrome

*S. Retamozo, P. Brito-Zerón, C. Morcillo, B. Kostov,
N. Acar-Denizli, M. Ramos-Casals*

1. Introduction	271
2. Esophageal Involvement	272
2.1 Dysphagia	272
2.2 Gastroesophageal Reflux	273
3. Gastric Involvement	273
3.1 Chronic Gastritis	273
3.2 <i>Helicobacter pylori</i> Infection	274

4. Intestinal Involvement	275
4.1 Association With Celiac Disease	275
4.2 Gastrointestinal Vasculitis	276
4.3 Protein-Losing Gastroenteropathy	277
5. Pancreatic Involvement	277
6. Liver Involvement	278
6.1 Chronic Hepatitis C Virus Infection	279
6.2 Chronic Hepatitis B Virus	280
6.3 Primary Biliary Cholangitis	281
6.4 Autoimmune Hepatitis	282
6.5 Other Autoimmune Liver Diseases	284
6.6 Evaluation of Altered Liver Profile in Patients With Sjögren's Syndrome	285
References	286
16. Gastrointestinal Involvement in Systemic Vasculitis	
<i>L. Quartuccio, S. De Vita</i>	
1. Introduction	293
2. Large-Vessel Vasculitis	294
2.1 Takayasu Arteritis	294
2.2 Giant Cell Arteritis	297
2.3 Chronic Periaortitis	300
3. Medium-Sized Vessel Vasculitis	302
3.1 Polyarteritis Nodosa	302
3.2 Kawasaki's Disease	304
4. Small-Sized Vessels Vasculitis	304
4.1 Henoch–Schönlein Purpura and Leukocytoclastic Vasculitis	305
4.2 ANCA-Associated Small-Vessel Vasculitis	306
4.3 Mixed Cryoglobulinemia, Hepatitis C Virus Infection, and Gastrointestinal Involvement	308
References	313
17. Mixed Connective Tissue Disease	
<i>J. Romero-Díaz, J. Sánchez-Guerrero</i>	
1. Introduction	321
2. Are Gastrointestinal Features a Common Manifestation of Mixed Connective Tissue Disease?	322
3. Oral Manifestations	324
4. Esophageal Dysfunction	324
5. Bowel Manifestations	327
6. Other Conditions	327
7. Therapeutic Considerations	328
8. Conclusion	329
References	329

18. Gastrointestinal Manifestations of Rheumatoid Arthritis	
<i>R.A. Ferrandiz, G.S. Alarcón</i>	
1. Introduction	333
2. Manifestations Directly Due to Rheumatoid Arthritis	333
3. Gastrointestinal Disease Resulting From Rheumatoid Arthritis Therapeutics	336
4. Mimics of Gastrointestinal Disease in Rheumatoid Arthritis	339
5. Conclusion	339
References	344
19. Spondyloarthritis and Gastrointestinal Involvement	
<i>F. Atzeni, R. Talotta, I.F. Masala, P. Sarzi-Puttini</i>	
1. Introduction	349
2. Prevalence and Epidemiology	349
3. Etiology/Pathogenesis	350
4. Clinical Manifestations	353
5. Diagnostic Investigations	354
5.1 Radiological	354
5.2 Functional Tests	355
5.3 Biochemistry/Serology/Immunology	355
6. Differential Diagnosis	356
7. Treatment	356
References	358
20. Intestinal Behçet's Disease	
<i>R. Hamad, H. Direskeneli, J. Al Saleh, M. Khamashta</i>	
1. Introduction	363
2. Epidemiology	363
3. Clinical Features	364
4. Differential Diagnosis	365
5. Pathogenesis	365
6. Diagnosis	367
6.1 Skin Pathergy Reaction	368
6.2 Inflammatory Markers	368
6.3 Imaging	368
6.4 Histopathology	369
7. Assessment of Severity	370
8. Management	370
8.1 Corticosteroids	370
8.2 Azathioprine	371
8.3 Anti-Tumor Necrosis Factor	372

8.4	Thalidomide	372
8.5	Surgical Treatment	372
9.	Prognosis	372
	References	372
21.	Gastrointestinal Involvement of Sarcoidosis	
	<i>R.P. Baughman, K. Bari</i>	
1.	Introduction	377
2.	Sarcoidosis of Upper Gastrointestinal Tract	377
3.	Sarcoidosis of Lower Gastrointestinal Tract	379
4.	Hepatic and Splenic Sarcoidosis	380
4.1	Histopathology and Pathogenesis	380
4.2	Clinical Features	383
4.3	Diagnosis	383
4.4	Differential Diagnosis	385
4.5	Treatment	386
5.	Conclusion	393
	References	393
22.	IgG4-Related Disease: Gastrointestinal Involvement	
	<i>P. Brito-Zerón, X. Bosch, M. Gandía, M.-J. Soto Cárdenas, M. Ramos-Casals, J.H. Stone</i>	
1.	Introduction	399
2.	Clinical Spectrum of IgG4-Gastrointestinal Disease	400
2.1	Sclerosing Sialadenitis	400
2.2	Esophageal Involvement	402
2.3	Gastric Involvement	403
2.4	Involvement of the Small Intestine	403
2.5	Involvement of the Large Intestine	403
2.6	Liver Involvement	403
2.7	Sclerosing Cholangitis	404
2.8	Cholecystitis	404
2.9	Autoimmune Pancreatitis	404
2.10	Intraabdominal Lymphadenopathy	404
3.	Diagnostic Approach	405
3.1	Imaging Studies	405
3.2	Laboratory Abnormalities	406
3.3	Histopathological Studies	406
3.4	Diagnostic Criteria	407
4.	Therapeutic Approach	407
	Acknowledgments	408
	References	408

23. Gastrointestinal Complications of Antirheumatic Drugs

K.D. Rainsford, I.R.L. Kean, W.F. Kean

1. Introduction	411
2. The Clinical Setting	412
2.1 Populations With Musculoskeletal Pain	412
2.2 Burdens of Analgesic and Antiinflammatory Medication Use	414
3. Gastrointestinal Reactions in Autoimmune Arthropathies	415
3.1 Multiple Origins of Gastrointestinal Reactions	415
3.2 Variation in Ulcerogenicity of NSAIDs	416
3.3 Mechanisms of Action of the NSAIDs	419
4. Gastrointestinal Reactions in Autoimmune Arthropathies	419
4.1 Multiple Origins of Gastrointestinal Reactions	420
4.2 Variation in Ulcerogenicity of NSAIDs	422
5. Coxibs Versus Nonselective NSAIDs	422
5.1 Pharmacological Rationale for Development of Coxibs	422
5.2 Potential for Impact of Arthritic Disease	424
5.3 Gastrointestinal Symptomatic Adverse Drug Reactions	425
5.4 Enter the Second-Generation Coxibs	426
6. Strategies to Minimize or Eliminate Gastrointestinal Complications	426
6.1 Effects of NSAIDs and <i>Helicobacter pylori</i> on Acid Secretion	427
6.2 Acid Secretion and Gastrin Production in Rheumatic Patients	428
6.3 Why Give Antisecretory Agents to Rheumatic Patients?	428
6.4 Risk Factors	429
6.5 Agents Used to Control Acid	429
7. Modification of Analgesics to Prevent Gastric Complications	433
8. Conclusion	434
References	434
Further Reading	445
Index	453